Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Post by Imarunawayon Aug 19, 2020 5:02pm
254 Views
Post# 31430720

Interesting!

Interesting! Below a post from a member on "Investors Hub"
Jama87   Tuesday, 08/18/20 10:43:38 AM
Re: None
Post #  of 9204 
 
At home clinical trial confirmed.


I was talking about this possibility in previous posts but now see it is on the clinical trial info, This may be the first at home Covid phase 3 trial.

From the clinical trial website:
Quote:


Patients qualifying for study enrollment will initiate therapy as outpatients, under home quarantine. Patients will receive continued standard care of therapy (per study site written policies or guidelines) together with bucillamine and/ or matching placebo for up to 14 days. Dosing should continue until the treatment course is completed or as medically indicated (e.g., deterioration of clinical status and alternative therapy required). If the patient requires hospitalization during the study period, treatment will be discontinued.



This Is the real deal. Other therapeutics are for people in critical condition but Bucillamine will be a take home therapy. Many more patients in this category of mild-moderate and much more revenue will be made vs other therapeutics. They even mention that hospitalized patients will be disqualified (I think once you are hospitalized you are not considered mild-moderate anymore) This is a whole new market of therapeutics that does not overlap with the other big therapeutics that are treating people in hospital If this is approved it will be stocked at every pharmacy in North America. Other big therapeutics (infusions and shots) are going to be administered in hospitals only and will not see the same volume of sales.

This could be similar to Tamiflu For influenza which sees $277 million in sales last year.



<< Previous
Bullboard Posts
Next >>